NCT01562561View on ClinicalTrials.gov

Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

June 1, 2001

Primary Completion Date

December 20, 2002

Study Completion Date

December 20, 2002

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

repaglinide

2 mg at each main meal

DRUG

insulin NPH

Administrated subcutaneously (s.c., under the skin) either at bedtime or twice daily at breakfast and before dinner.

Trial Locations (12)

710

Novo Nordisk Investigational Site, Tainan City

1100

Novo Nordisk Investigational Site, Quezon City

1449

Novo Nordisk Investigational Site, Alberton

1605

Novo Nordisk Investigational Site, Pasig

1800

Novo Nordisk Investigational Site, Marikina City

2193

Novo Nordisk Investigational Site, Johannesburg

4001

Novo Nordisk Investigational Site, Durban

7460

Novo Nordisk Investigational Site, Cape Town

16150

Novo Nordisk Investigational Site, Kota Bharu, Kelantan

Unknown

Novo Nordisk Investigational Site, Shatin, New Territories

Novo Nordisk Investigational Site, Pretoria

0250

Novo Nordisk Investigational Site, Brits

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01562561 - Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter